癌症患者中心静脉导管置管后置管相关性血栓的独立危险因素分析
Analysis of Independent Risk Factors for Catheter-Related Thrombosis in Cancer Patients after Central Venous Catheter Placement
DOI: 10.12677/acm.2026.162531, PDF,    科研立项经费支持
作者: 张涵蕴, 杨 梅*, 庄钰春, 汤璐羽, 陈 露:北京大学肿瘤医院云南医院/云南省肿瘤医院/昆明医科大学第三附属医院I期临床试验病房,云南 昆明
关键词: 癌症中心静脉导管置管相关性血栓形成危险因素Cancer Central Venous Catheter Catheter-Related Thrombosis Risk Factors
摘要: 背景:癌症患者由于肿瘤微环境变化处于高凝状态,导致静脉血栓发生率增高。随着中心静脉导管(CVC)置管的广泛应用,置管相关性血栓形成(CRT)发生率也随之升高,但CVC置管相关性血栓形成(CRT)的危险因素仍不清楚。目的:本研究拟通过对癌症患者中心静脉导管(CVC)置管后血栓形成(CRT)的发生率及危险因素的分析,为临床识别高风险患者、实施早期干预、提升患者生存质量提供依据。方法:回顾性分析2020年1月1日至2025年1月1日期间254名癌症患者的临床资料,分为血栓组和非血栓组,采用卡方检验或t检验分析各因素与CRT的关系,并通过二元logistic回归进行多因素变量分析。结果:在中位导管留置时间为4天的情况下,92例(36.2%)患者发生CRT,血栓主要位于右侧颈内静脉下段及中下段。单因素分析显示,VTE评分、纤维蛋白原水平、甘油三酯、总胆固醇、低密度脂蛋白及导管留置时间与CRT相关(P < 0.05)。多因素分析确认,纤维蛋白原水平(OR = 5.75, 95% CI: 2.82~11.73, P < 0.001)、甘油三酯(OR = 4.49, 95% CI: 1.89~10.71, P < 0.001)及导管留置时间(OR = 4.7, 95% CI: 2.37~9.32, P < 0.001)为CRT的独立危险因素(导管留置时间以天为单位)。结论:纤维蛋白原升高、高甘油三酯及较长的导管留置时间与CRT形成正相关。这些发现为临床风险评估和管理提供了重要依据,提示在治疗过程中需特别关注这些因素,以改善恶性肿瘤患者的预后。
Abstract: Background: Cancer patients are in a hypercoagulable state due to changes in the tumor microenvironment, resulting in an increased incidence of venous thrombosis. With the widespread use of central venous catheters (CVCs), the incidence of catheter-related thrombosis (CRT) has also increased, but the risk factors for CVC-related thrombosis remain unclear. Objective: This study aims to analyze the incidence and risk factors of catheter-related thrombosis (CRT) in cancer patients following CVC placement, to provide a basis for clinical identification of high-risk patients, early intervention, and improvement of patient quality of life. Methods: A retrospective analysis was conducted on the clinical data of 254 cancer patients from January 1, 2020, to January 1, 2025. Patients were divided into thrombosis and non-thrombosis groups. Chi-square test or t-test was used to analyze the relationship between various factors and CRT, and multivariate analysis was performed using binary logistic regression. Results: Among patients with a median catheter indwelling time of 4 days, 92 patients (36.2%) developed CRT, with thrombosis primarily located in the lower and middle-lower segments of the right internal jugular vein. Univariate analysis showed that VTE score, fibrinogen level, triglycerides, total cholesterol, low-density lipoprotein, and catheter indwelling time were associated with CRT (P < 0.05). Multivariate analysis confirmed that fibrinogen level (OR = 5.75, 95% CI: 2.82~11.73, P < 0.001), triglycerides (OR = 4.49, 95% CI: 1.89~10.71, P < 0.001), and catheter indwelling time (OR = 4.7, 95% CI: 2.37~9.32, P < 0.001) were independent risk factors for CRT (catheter indwelling time in days). Conclusion: Elevated fibrinogen, high triglycerides, and longer catheter indwelling time are positively correlated with CRT. These findings provide important evidence for clinical risk assessment and management, indicating that special attention should be paid to these factors during treatment to improve the prognosis of patients with malignant tumors.
文章引用:张涵蕴, 杨梅, 庄钰春, 汤璐羽, 陈露. 癌症患者中心静脉导管置管后置管相关性血栓的独立危险因素分析[J]. 临床医学进展, 2026, 16(2): 1440-1449. https://doi.org/10.12677/acm.2026.162531

参考文献

[1] Kolikof, J., Peterson, K., Williams, C., et al. (2025) Central Venous Catheter Insertion. StatPearls Publishing.
[2] Saber, W., Moua, T., Williams, E.C., Verso, M., Agnelli, G., Couban, S., et al. (2011) Risk Factors for Catheter‐Related Thrombosis (CRT) in Cancer Patients: A Patient‐Level Data (IPD) Meta‐analysis of Clinical Trials and Prospective Studies. Journal of Thrombosis and Haemostasis, 9, 312-319. [Google Scholar] [CrossRef] [PubMed]
[3] Debourdeau, P., Farge, D., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., et al. (2013) International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer. Journal of Thrombosis and Haemostasis, 11, 71-80. [Google Scholar] [CrossRef] [PubMed]
[4] Teja, B., Bosch, N.A., Diep, C., Pereira, T.V., Mauricio, P., Sklar, M.C., et al. (2024) Complication Rates of Central Venous Catheters. JAMA Internal Medicine, 184, 474-482. [Google Scholar] [CrossRef] [PubMed]
[5] Taglialatela, I., Mariani, L., Dotti, K.F., Di Vico, L., Pisanu, M.N., Facchinetti, C., et al. (2023) Central Venous Catheters-Related-Thrombosis and Risk Factors in Oncological Patients: A Retrospective Evaluation of Recent Risk Scores. Tumori Journal, 109, 363-369. [Google Scholar] [CrossRef] [PubMed]
[6] Debourdeau, P., Lamblin, A., Debourdeau, T., Marcy, P.Y. and Vazquez, L. (2021) Venous Thromboembolism Associated with Central Venous Catheters in Patients with Cancer: From Pathophysiology to Thromboprophylaxis, Areas for Future Studies. Journal of Thrombosis and Haemostasis, 19, 2659-2673. [Google Scholar] [CrossRef] [PubMed]
[7] Dave, H.M. and Khorana, A.A. (2024) Management of Venous Thromboembolism in Patients with Active Cancer. Cleveland Clinic Journal of Medicine, 91, 109-117. [Google Scholar] [CrossRef] [PubMed]
[8] Farag, M.M., Ghazal, H.A.E.R., Radwan, M.M. and El-Sayed, N.S. (2024) Catheters Linked Thrombosis in Neonates: A Single Center Observational Study. Italian Journal of Pediatrics, 50, Article No. 174. [Google Scholar] [CrossRef] [PubMed]
[9] Couban, S., Goodyear, M., Burnell, M., Dolan, S., Wasi, P., Barnes, D., et al. (2005) Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter—Associated Thrombosis in Patients with Cancer. Journal of Clinical Oncology, 23, 4063-4069. [Google Scholar] [CrossRef] [PubMed]
[10] Karthaus, M., Kretzschmar, A., Kröning, H., Biakhov, M., Irwin, D., Marschner, N., et al. (2006) Dalteparin for Prevention of Catheter-Related Complications in Cancer Patients with Central Venous Catheters: Final Results of a Double-Blind, Placebo-Controlled Phase III Trial. Annals of Oncology, 17, 289-296. [Google Scholar] [CrossRef] [PubMed]
[11] Lokich, J.J. and Becker, B. (1983) Subclavian Vein Thrombosis in Patients Treated with Infusion Chemotherapy for Advanced Malignancy. Cancer, 52, 1586-1589. [Google Scholar] [CrossRef] [PubMed]
[12] Bern, M.M., Lokich, J.J., Wallach, S.R., Bothe, A., Benotti, P.N., Arkin, C.F., et al. (1990) Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters. Annals of Internal Medicine, 112, 423-428. [Google Scholar] [CrossRef] [PubMed]
[13] Fagnani, D., Franchi, R., Porta, C., Pugliese, P., Borgonovo, K., Bertolini, A., et al. (2007) Thrombosis-Related Complications and Mortality in Cancer Patients with Central Venous Devices: An Observational Study on the Effect of Antithrombotic Prophylaxis. Annals of Oncology, 18, 551-555. [Google Scholar] [CrossRef] [PubMed]
[14] Lee, A.Y.Y., Levine, M.N., Butler, G., Webb, C., Costantini, L., Gu, C., et al. (2006) Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients with Cancer. Journal of Clinical Oncology, 24, 1404-1408. [Google Scholar] [CrossRef] [PubMed]
[15] Peng, M., Yang, S., Li, G., Zhang, T., Qin, X., Shi, C., et al. (2021) Solid Tumor Complicated with Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study. Clinical and Applied Thrombosis/Hemostasis, 27, 1-8. [Google Scholar] [CrossRef] [PubMed]
[16] Kuter, D.J. (2004) Thrombotic Complications of Central Venous Catheters in Cancer Patients. The Oncologist, 9, 207-216. [Google Scholar] [CrossRef] [PubMed]
[17] Falanga, A., Marchetti, M. and Russo, L. (2015) The Mechanisms of Cancer-Associated Thrombosis. Thrombosis Research, 135, S8-S11. [Google Scholar] [CrossRef] [PubMed]
[18] Mukai, M. and Oka, T. (2018) Mechanism and Management of Cancer-Associated Thrombosis. Journal of Cardiology, 72, 89-93. [Google Scholar] [CrossRef] [PubMed]
[19] Olson, J. (2015) D-Dimer: An Overview of Hemostasis and Fibrinolysis, Assays, and Clinical Applications. Advances in Clinical Chemistry, 69, 1-46.
[20] Maekawa, T., Kobayashi, N., Arai, H. and Takeuchi, T. (1976) Role of Blood Platelet in the Formation of Thrombus. Thrombosis Research, 8, 227-234. [Google Scholar] [CrossRef] [PubMed]
[21] 杨佳, 王梅林, 陈晓琳, 等. 预防性应用抗凝药物对乳腺癌PICC相关性血栓形成的影响[J]. 齐鲁护理杂志, 2018, 24(8): 30-32.
[22] 张梦可, 李欢欢, 向明丽, 等. 急性白血病患儿经外周静脉穿刺的中心静脉导管置管后发生静脉血栓栓塞的影响因素分析及预测模型构建[J]. 癌症进展, 2025, 23(1): 63-67.
[23] Hempel, G., Neef, M., Rotzoll, D. and Heinke, W. (2013) Study of Medicine 2.0 Due to Web 2.0?!—Risks and Opportunities for the Curriculum in Leipzig. GMS Zeitschrift für Medizinische Ausbildung, 30, Doc11.